COMMUNIQUÉS West-GlobeNewswire

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
31/07/2025
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP [...]
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
31/07/2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
31/07/2025
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp [...]
XORTX Announces USD $114,500 Private Placement
31/07/2025
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Teleflex Announces Quarterly Dividend
31/07/2025
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
31/07/2025
$12.5 million in second quarter PYRUKYND ® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, [...]
Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook
31/07/2025
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue [...]
ICPO and SBMN deepen their collaboration to advance Clinical Theranostics Centers of Excellence in Brazil
31/07/2025
ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start. July 31, 2025 – Wiesbaden, Germany, and Sao Paulo, Brazil. During the [...]
SAFE - Informations complémentaires concernant le report de publication des résultats annuels 2024
31/07/2025
Informations complémentaires concernant le report de publication des résultats annuels 2024 Fleurieux-sur-l’Arbresle – France – 31 juillet 2025 à 12h - Safe (FR001400RKU0 – ALSAF) annonce qu’elle devrait disposer de l’ [...]
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
31/07/2025
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities [...]
Integra LifeSciences Reports Second Quarter 2025 Financial Results
31/07/2025
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending [...]
PL BioScience Announces Major Site Expansion
31/07/2025
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production Site provides the world’s largest HPL output with 20,000L annual capacity and a dual-source GMP [...]
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
31/07/2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering [...]
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
31/07/2025
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER 1 and business EPS 2 of €1.59 Pharma [...]
Communiqué de presse : T2 : croissance à deux chiffres desventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre
31/07/2025
T2 : croissance à deux chiffres des ventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre [...]
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025
31/07/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 [...]
Pharming Group reports second quarter and first half 2025 financial results and provides business update
31/07/2025
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue increased by 28% to US$ [...]
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
31/07/2025
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive [...]
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
31/07/2025
H1 total sales growth of 11.4% at CER 1 , or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9 [...]

Pages